TABLE OF CONTENTS
1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 OVERVIEW OF EUROPE EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET 15
1.4 LIMITATIONS 17
1.5 MARKETS COVERED 17
2 MARKET SEGMENTATION 20
2.1 MARKETS COVERED 20
2.2 GEOGRAPHICAL SCOPE 21
2.3 YEARS CONSIDERED FOR THE STUDY 22
2.4 CURRENCY AND PRICING 22
2.5 DBMR TRIPOD DATA VALIDATION MODEL 23
2.6 MULTIVARIATE MODELLING 26
2.7 PRODUCT TYPE LIFELINE CURVE 26
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 27
2.9 DBMR MARKET POSITION GRID 28
2.10 MARKET TESTING TYPE COVERAGE GRID 29
2.11 VENDOR SHARE ANALYSIS 30
2.12 SECONDARY SOURCES 31
2.13 ASSUMPTIONS 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHTS 34
4.1 PESTEL ANALYSIS 35
4.2 PORTER ANALYSIS 36
5 INDUSTRY INSIGHTS 37
6 REGULATORY FRAMEWORK 39
7 MARKET OVERVIEW 41
7.1 DRIVERS 43
7.1.1 INCREASING PREVALENCE OF EXOCRINE PANCREATIC INSUFFICIENCY (EPI) DUE TO CHRONIC PANCREATITIS AND CYSTIC FIBROSIS 43
7.1.2 RISING TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSIS AND TREATMENT OF EPI 43
7.1.3 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYERS 44
7.1.4 SEDENTARY LIFESTYLES AND UNHEALTHY DIETS 44
7.2 RESTRAINTS 45
7.2.1 STRINGENT REGULATIONS TO HAMPER THE EXOCRINE PANCREATIC INSUFFICIENCY(EPI) THERAPEUTIC AND DIAGNOSTIC SECTOR 45
7.2.2 SIDE EFFECTS AND RELIGIOUS HURDLES ASSOCIATED WITH PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) 45
7.3 OPPORTUNITIES 46
7.3.1 INCREASING PREVALENCE OF PANCREATIC DISORDERS AND ASSOCIATED CONDITION 46
7.3.2 RISING AWARENESS ABOUT THE BENEFITS OF EARLY DIAGNOSIS AND TREATMENT OF EPI 46
7.3.3 GROWING DEMAND FOR COMBINATION THERAPIES AND PERSONALIZED MEDICINE 47
7.4 CHALLENGES 48
7.4.1 HIGH COST ASSOCIATED WITH EPI DIAGNOSIS AND TREATMENT 48
7.4.2 LIMITED AVAILABILITY OF EPI THERAPEUTICS AND DIAGNOSTICS 48
8 EUROPE EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY TREATMENT 49
8.1 OVERVIEW 50
8.2 PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) 53
8.2.1 BY ENZYME 53
8.2.1.1 LIPASE 54
8.2.1.2 PROTEASE 54
8.2.1.3 AMYLASE 54
8.2.2 BY ROUTE OF ADMINISTRATION 54
8.2.2.1 ORAL 55
8.2.2.1.1 CAPSULES 55
8.2.2.1.2 TABLETS 55
8.2.2.1.3 POWDER 55
8.2.2.2 INTRAVENOUS 55
8.3 NUTRITIONAL MANAGEMENT 56
8.3.1 VITAMIN D 57
8.3.2 VITAMIN E 57
8.3.3 VITAMIN A 57
8.3.4 VITAMIN K 57
8.3.5 OTHERS 57
9 EUROPE EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS 58
9.1 OVERVIEW 59
9.2 PANCREATIC FUNCTION TEST 61
9.2.1 STOOL 62
9.2.1.1 FECAL ELASTASE TEST 63
9.2.1.2 FECAL FAT TEST 63
9.2.2 SECRETIN PANCREATIC FUNCTION TEST 63
9.2.3 BLOOD TESTS 63
9.2.4 C-MIXED TRIGLYCERIDES BREATH TEST 63
9.2.5 FASTING PLASMA GLUCOSE TEST 63
9.3 IMAGING TEST 63
9.3.1 CT SCANNING 65
9.3.2 MAGNETIC RESONANCE IMAGING TESTS (MRI) 65
9.3.3 ENDOSCOPIC RETROGRADE PANCREATOGRAPHY 65
9.3.4 ENDOSCOPIC ULTRA-SONOGRAPHY (EUS) 65
9.3.5 SECRETIN-STIMULATED MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY 65
10 EUROPE EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DRUG TYPE 66
10.1 OVERVIEW 67
10.2 BRANDED 69
10.2.1 CREON 70
10.2.2 ZENPEP 71
10.2.3 PANCREAZE 71
10.2.4 NUTRIZYM 71
10.2.5 PANCREASE MT 71
10.2.6 PANCREX 71
10.2.7 COTAZYM 71
10.2.8 ULTERSA 71
10.2.9 VIOKACE 71
10.2.10 PERTZYE 71
10.2.11 OTHERS 72
10.3 GENERIC 72
11 EUROPE EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY END USER 73
11.1 OVERVIEW 74
11.2 HOSPITALS 76
11.2.1 PRIVATE 77
11.2.2 PUBLIC 77
11.3 SPECIALTY CLINICS 77
11.4 DIAGNOSTIC CENTER 78
11.5 HOMECARE 79
11.6 RESEARCH AND ACADEMIC INSTITUTES 80
11.7 OTHERS 81
12 EUROPE EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 82
12.1 OVERVIEW 83
12.2 DIRECT TENDER 85
12.3 RETAIL PHARMACY 86
12.4 THIRD PARTY DISTRIBUTORS 87
12.5 OTHERS 88
13 EUROPE EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION 89
13.1 EUROPE 90
13.1.1 GERMANY 95
13.1.2 FRANCE 95
13.1.3 U.K. 95
13.1.4 ITALY 95
13.1.5 SPAIN 95
13.1.6 RUSSIA 95
13.1.7 TURKEY 95
13.1.8 BELGIUM 95
13.1.9 DENMARK 95
13.1.10 NETHERLANDS 96
13.1.11 SWITZERLAND 96
13.1.12 SWEDEN 96
13.1.13 POLAND 96
13.1.14 NORWAY 96
13.1.15 FINLAND 96
13.1.16 REST OF EUROPE 96
14 EUROPE EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: COMPANY LANDSCAPE 97
14.1 COMPANY SHARE ANALYSIS: EUROPE 97
15 SWOT ANALYSIS 98
16 COMPANY PROFILE 99
16.1 ABBVIE INC. 99
16.1.1 COMPANY SNAPSHOT 99
16.1.2 REVENUE ANALYSIS 99
16.1.3 COMPANY SHARE ANALYSIS 100
16.1.4 PRODUCT PORTFOLIO 100
16.1.5 RECENT DEVELOPMENT 100
16.2 ABBOTT 101
16.2.1 COMPANY SNAPSHOT 101
16.2.2 REVENUE ANALYSIS 101
16.2.3 COMPANY SHARE ANALYSIS 102
16.2.4 PRODUCT PORTFOLIO 102
16.2.5 RECENT DEVELOPMENT 102
16.3 NESTLE 103
16.3.1 COMPANY SNAPSHOT 103
16.3.2 REVENUE ANALYSIS 103
16.3.3 COMPANY SHARE ANALYSIS 104
16.3.4 PRODUCT PORTFOLIO 104
16.3.5 RECENT DEVELOPMENTS 104
16.4 LABORATORY CORPORATION OF AMERICA HOLDINGS (2022) 105
16.4.1 COMPANY SNAPSHOT 105
16.4.2 REVENUE ANALYSIS 105
16.4.3 COMPANY SHARE ANALYSIS 106
16.4.4 PRODUCT PORTFOLIO 106
16.4.5 RECENT DEVELOPMENT 106
16.5 JANSSEN EUROPE SERVICES, LLC 107
16.5.1 COMPANY SNAPSHOT 107
16.5.2 REVENUE ANALYSIS 107
16.5.3 COMPANY SHARE ANALYSIS 108
16.5.4 PRODUCT PORTFOLIO 108
16.5.5 RECENT DEVELOPMENT 108
16.6 ALCRESTA THERAPEUTICS, INC. 109
16.6.1 COMPANY SNAPSHOT 109
16.6.2 COMPANY SHARE ANALYSIS 109
16.6.3 PRODUCT PORTFOLIO 110
16.6.4 RECENT DEVELOPMENT 110
16.7 BIOSERV DIAGNOSTICS GMBH 111
16.7.1 COMPANY SNAPSHOT 111
16.7.2 PRODUCT PORTFOLIO 111
16.7.3 RECENT DEVELOPMENT 111
16.8 CILIAN AG 112
16.8.1 COMPANY SNAPSHOT 112
16.8.2 PRODUCT PORTFOLIO 112
16.8.3 RECENT DEVELOPMENT 112
16.9 CHIRHOCLIN 113
16.9.1 COMPANY SNAPSHOT 113
16.9.2 COMPANY SHARE ANALYSIS 113
16.9.3 PRODUCT PORTFOLIO 114
16.9.4 RECENT DEVELOPMENT 114
16.10 DIGESTIVE CARE, INC. 115
16.10.1 COMPANY SNAPSHOT 115
16.10.2 PRODUCT PORTFOLIO 115
16.10.3 RECENT DEVELOPMENT 115
16.11 EAGLEBIO 116
16.11.1 COMPANY SNAPSHOT 116
16.11.2 PRODUCT PORTFOLIO 116
16.11.3 RECENT DEVELOPMENT 116
16.12 METAGENICS LLC 117
16.12.1 COMPANY SNAPSHOT 117
16.12.2 PRODUCT PORTFOLIO 117
16.12.3 RECENT DEVELOPMENT 117
16.13 NORDMARK 118
16.13.1 COMPANY SNAPSHOT 118
16.13.2 COMPANY SHARE ANALYSIS 118
16.13.3 PRODUCT PORTFOLIO 119
16.13.4 RECENT DEVELOPMENT 119
16.14 ORGANON GROUP OF COMPANIES. 120
16.14.1 COMPANY SNAPSHOT 120
16.14.2 REVENUE ANALYSIS 120
16.14.3 PRODUCT PORTFOLIO 121
16.14.4 RECENT DEVELOPMENT 121
16.15 SCHEBO BIOTECH AG 122
16.15.1 COMPANY SNAPSHOT 122
16.15.2 PRODUCT PORTFOLIO 122
16.15.3 RECENT DEVELOPMENT 122
16.16 VIVUS LLC 123
16.16.1 COMPANY SNAPSHOT 123
16.16.2 COMPANY SHARE ANALYSIS 123
16.16.3 PRODUCT PORTFOLIO 124
16.16.4 RECENT DEVELOPMENT 124
17 QUESTIONNAIRE 125
18 RELATED REPORTS 128

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.